Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Human Clinical Study of Its High Absorption TurboCBD Capsules

• Study will measure the cardiovascular and cognitive health effects of patented DehydraTECH, its disruptive delivery technology
• Data generated will help company’s development of next-generation cannabinoid product formulations
• Chris Bunka, CEO, and John Docherty, president, to present at the ‘Next Generation Nicotine Delivery USA 2018’ conference in Atlanta on April 24 and 25

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has started a human clinical study in Europe on the health effects of its high absorption TurboCBD™ capsules. LXRP, a drug delivery platform innovator, will be conducting the study to evaluate the cardiovascular and cognitive health effects of its patented DehydraTECH™ technology, the company announced (http://ibn.fm/CocLR).

The study will measure the impact of the TurboCBD capsules on vascular function and cognitive performance improvement. The same DehydraTECH technology used in this study was utilized in the company’s recent rodent-based nicotine-absorption study. The two studies exhibit the wide applicability of LXRP’s proprietary drug delivery platform, the company said.

Based in British Columbia, Canada, LXRP out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids.

The company will present on April 24 and 25 in Atlanta the results of its recent ingestible nicotine absorption study. At the ‘Next Generation Nicotine Delivery USA 2018’ conference, LXRP’s Chris Bunka, CEO, and John Docherty, president, will speak (http://ibn.fm/Pz5RM).

Recently, LXRP conducted a lab study on animals that evaluated DehydraTECH technology as an alternative nicotine delivery method. Top line results showed that it might have potential as a possible nicotine replacement therapy.

Depending on results of the European human study, a second phase clinical study on the elderly may be conducted in later 2018, LXRP said.

For more information, visit the company’s website at www.LexariaBioscience.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php